



NEWS RELEASE

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox Pharmaceutical to Present at the Growth and Value Investor Conference

HASBROUCK HEIGHTS, NJ (February 14, 2008) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company will present at the 2008 Growth & Value Investor Conference to be held in at the Westin Fort Lauderdale, Fort Lauderdale, FL on February 27 and 28. At the Conference, the Company's CEO, Paul Averbach, MD, will provide an overview of the Company's recent progress in drug development. The Growth & Value Investor Conference is hosted by LDV Capital Management in cooperation with the Stock and Bond Club of South Florida and is expected to attract 1,000 to 1,500 investment professionals.

Nymox recently announced positive results from a prospective randomized Phase 2 trial of NX-1207, its drug in development for benign prostatic hyperplasia (BPH). In that trial involving 32 sites across the U.S., a single dose treatment of NX-1207 showed statistically significant superiority to finasteride, a widely marketed approved treatment for BPH. Patients given a therapeutic dose of NX-1207 showed a markedly better mean improvement in their BPH symptom scores in comparison to finasteride (9.71 points vs. 4.13 points; intent-to-treat group). This difference was statistically significant ($p=0.001$). These patients also had statistically significant mean reduction in prostate volume and increase in peak urine flow after 90 days as compared to before treatment.

The results of this trial are consistent with the previous results of three other U.S. trials and 5 follow-up studies for NX-1207. In the Company's earlier Phase 2 double-blind, placebo controlled, randomized multi-center U.S. trial, patients treated with NX-1207 showed after 90 days a statistically significant mean improvement in BPH symptom score (9.35 points) and a statistically significant reduction in mean prostate volume. A recently completed follow-up study of available subjects from this Phase 2 study showed evidence of durable benefit from NX-1207 treatment. The blinded placebo-controlled follow-up study assessed treatment outcomes 16 to 27 months after a single treatment with NX-1207 or placebo. At the time of follow-up, 52% of patients treated with NX-1207 were not on BPH medication and had not required surgical intervention for their BPH since their initial treatment with NX-1207; these patients had a mean improvement of 10.2 points in AUA BPH Symptom Score values.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.